BUB1B and prostate carcinoma: Also, studies have shown that overexpression of BUB1B (budding uninhibited by benzimidazole-related 1) was associated with progression of bladder cancer (Yamamoto et al., 2007), hepatocellular carcinoma (Liu et al., 2009), and prostate cancer (Fu et al., 2016).